Is ALIM stock a buy right now?
2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last year. There are currently 2 buy rati...
Will Alimera Sciences' stock price go up in 2022?
2 brokerages have issued 1-year price targets for Alimera Sciences' stock. Their forecasts range from $8.00 to $11.00. On average, they anticipate...
How has Alimera Sciences' stock performed in 2022?
Alimera Sciences' stock was trading at $5.13 at the beginning of the year. Since then, ALIM stock has increased by 18.9% and is now trading at $6.1...
When is Alimera Sciences' next earnings date?
Alimera Sciences is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022. View our earnings forecast for Alim...
How were Alimera Sciences' earnings last quarter?
Alimera Sciences, Inc. (NASDAQ:ALIM) released its earnings results on Monday, May, 9th. The biopharmaceutical company reported ($0.85) earnings per...
When did Alimera Sciences' stock split? How did Alimera Sciences' stock split work?
Alimera Sciences's stock reverse split before market open on Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November...
Who are Alimera Sciences' key executives?
Alimera Sciences' management team includes the following people: Mr. Charles Daniel Myers , Non-Exec. Chairman & Consultant (Age 68, Pay $205k)...
What is Rick Eiswirth's approval rating as Alimera Sciences' CEO?
2 employees have rated Alimera Sciences CEO Rick Eiswirth on Glassdoor.com . Rick Eiswirth has an approval rating of 100% among Alimera Sciences'...
Who are some of Alimera Sciences' key competitors?
Some companies that are related to Alimera Sciences include Immuneering (IMRX) , KemPharm (KMPH) , Savara (SVRA) , 9 Meters Biopharma (NMTR) ,...
How much cash does Alimera have in 2021?
When is Alimera's earnings call 2021?
Cash and Cash EquivalentsOn March 31, 2021, Alimera had cash and cash equivalents of approximately $8.3 million dollars, compared to $11.2 million in cash and cash equivalents on December 31, 2020.
When will the Alimera replay be available?
NEW YORK, NY / ACCESSWIRE / April 29, 2021 / Alimera Sciences, Inc. (NASDAQ:ALIM) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on April 29, 2021 at 9:00 AM Eastern Time.
How early can you dial in to Alimera Sciences?
The telephonic replay will be available until May 13, 2021. About Alimera Sciences, Inc. Alimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals.
Signals & Forecast
All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Alimera Sciences call. The conference call will also be available through a live webcast which is also available through the company’s website.
Support, Risk & Stop-loss
The Alimera Sciences stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock.
Is Alimera Sciences stock A Buy?
Alimera Sciences finds support from accumulated volume at $4.63 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Insiders are positive buying more shares than they are selling in Alimera Sciences
Alimera Sciences holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
About Alimera Sciences
In the last 100 trades there were 721.26 thousand shares bought and 274.75 thousand shares sold. The last trade was done 18 days ago by Morgan Stanley who sold 250 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Golden Star Signal
Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States, Germany, Portugal, and the United Kingdom. The company focuses on diseases affecting the back of the eye or retina.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Nasdaq Global Market
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
Environmental, Social, and Governance Rating
Alimera Sciences Inc. is a biopharmaceutical company that engaged in the research development and commercialization of ophthalmic pharmaceuticals.
Business Summary
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
Component Grades
Alimera Sciences Inc. is a biopharmaceutical company that engaged in the research development and commercialization of ophthalmic pharmaceuticals.
ALIM Stock Summary
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
ALIM Valuation Summary
With a market capitalization of $32,470,561, Alimera Sciences Inc has a greater market value than just 6.39% of US stocks.
News
In comparison to the median Healthcare stock, ALIM's price/earnings ratio is 50.96% lower, now standing at 17.9.
Trending Stocks
Alimera Sciences is a pharmaceutical company focused on commercializing and developing treatments that address diseases affecting the back of the eye (retina). ILUVIEN (R) is Alimera's a patented micro-implant which delivers a continuous, low dose anti-inflammatory agent to the retina for up to 3 years.
Ideas
Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these sessions may offer less liquidity and inferior prices. Stock prices may also move more quickly in this environment.
Profile
Bounce off support supplemented w/ news of large prive equity placement of up to $20M; $1M already purchased @.5/ 35% higher current SP!
